<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108558</url>
  </required_header>
  <id_info>
    <org_study_id>CUREPD 103</org_study_id>
    <nct_id>NCT05108558</nct_id>
  </id_info>
  <brief_title>Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders</brief_title>
  <official_title>Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders: A Randomized, Controlled, Single-Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charitable Union for the Research and Education of Peyronie's Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charitable Union for the Research and Education of Peyronie's Disease</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare key clinical outcomes between controls and men treated with a novel CCH&#xD;
      administration protocol among men previously unresponsive to CCH administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Beginning approximately 3 years ago, the investigators' team sought to achieve further&#xD;
      improvements with CCH through the addition of more aggressive modeling therapies. Results&#xD;
      from a comparison of CCH alone vs CCH and traction with RestoreX demonstrated a mean 33.8&#xD;
      degree (49%) curvature improvement with combined therapy compared to 19-20 degrees (30-31%)&#xD;
      with CCH alone or CCH and other traction devices). These results currently represent the&#xD;
      greatest improvements with CCH in published literature and further build upon phase IIb&#xD;
      results which demonstrated that mechanical traction (via manual modeling in the phase IIb&#xD;
      trial) represents a critical factor in achieving improvements with CCH.&#xD;
&#xD;
      The investigators' team additionally published a survey of men who had experienced suspected&#xD;
      penile fractures with CCH and demonstrated greater curvature improvements without any loss /&#xD;
      worsening of erectile function. This critical study highlighted that conservative management&#xD;
      of suspected fractures should not only be considered a standard of care in managing suspected&#xD;
      fractures, but also that these men achieved better final outcomes (again highlighting the&#xD;
      importance of the combination of mechanical curvature correction in addition to CCH&#xD;
      management).&#xD;
&#xD;
      Based on the above findings, the investigators' team began performing a more aggressive&#xD;
      manual modeling protocol. This novel protocol included several notable innovations: dilution&#xD;
      of the 0.9 mg of CCH in 0.7 ml of diluent, injection to the erect penis to assure accurate&#xD;
      injection, repeat curvature assessments with each series (due to changing of the point of&#xD;
      maximal curvature), incorporation of RestoreX traction therapy post injection, and&#xD;
      'aggressive' manual modeling (equivalent of 10-15 lbs of force) to achieve curvature&#xD;
      correction. Preliminary (unpublished - abstract submitted to SMSNA 2021) results from these&#xD;
      men demonstrated a median ~60% curvature improvement. Importantly, several of the patients&#xD;
      had previously undergone 8 CCH injections with outside providers and were able to similarly&#xD;
      achieve a median 60% improvement with the investigators' injection / modeling protocol.&#xD;
&#xD;
      These preliminary findings have several important ramifications for the treatment of PD:&#xD;
&#xD;
        1. Men who have previously not achieved adequate curvature correction with 4 series of CCH&#xD;
           injections may benefit from additional injections using a more aggressive traction&#xD;
           protocol.&#xD;
&#xD;
        2. A more aggressive traction protocol would benefit patients to achieve greater outcomes&#xD;
           than with previously reported protocols.&#xD;
&#xD;
      1.2 Investigational Treatments&#xD;
&#xD;
      The current study would randomize men 1:3 into one of two treatment cohorts: 1. Observation&#xD;
      followed by CCH or 2. CCH followed by observation. This study design offers the benefits of a&#xD;
      randomized, controlled trial (highest level of evidence). RCTs are particularly important in&#xD;
      PD, where the disease changes over time in a percentage of men as a function of its natural&#xD;
      history. This would also allow blinding of measurements using photographs (single-blinded&#xD;
      assessments), which provides further study rigor.&#xD;
&#xD;
        1. No treatment (control) followed by CCH. Men in this cohort would undergo baseline&#xD;
           assessments followed by no treatment for 6 months and then repeat assessments. Men would&#xD;
           then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is&#xD;
           &lt;15 degrees). Interval assessments would be performed with the 1st injection of each&#xD;
           series, and final assessments would then be performed 6 weeks following the final&#xD;
           injection.&#xD;
&#xD;
        2. CCH followed by no treatment. Men in this cohort would undergo baseline assessments&#xD;
           followed by up to 8 injections of CCH (or until curvature is &lt;15 degrees). Interval&#xD;
           assessments would be performed with the 1st injection of each series and 6 weeks&#xD;
           following completion of treatment. Men then would not undergo any additional treatments&#xD;
           for 6 months, after which final assessments would then performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients meeting criteria who have consented will be randomized to either control or CCH x 6 months, followed by a cross-over phase where controls will receive CCH. See Figure 1 for full study schema.&#xD;
Control. Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to the CCH treatment phase and undergo up to 8 injections (or until curvature is &lt;15 degrees, whichever comes first). Final assessments would then be performed 6 weeks following the final injection.&#xD;
CCH followed by observation. Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is &lt;15 degrees). Assessments would then be performed 6 weeks after completion of treatment. Men then would not undergo any additional treatments for 6 months, after which they would have final assessments performed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
    <masking_description>Photography will be obtained where possible, with outcomes assessed based on the photographs. The care provider obtaining measurements will also be blinded as to baseline outcomes and results with follow-up assessments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Penile Curvature</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the change in degree of penile curvature from baseline (using a goniometer) between control and treatment groups at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peyronie's Disease Questionnaire Outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Compare Peyronie's Disease Questionnaire outcomes between control and treatment groups at 6 months using the Peyronie's Disease Questionnaire (15 items; subdomains - psychological and physical (Q1-6, 0-24), penile pain (Q7-9; 0-30), symptom bother (Q10-15; 0-16); 12 and 14 (Y/N q's); lower is better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function Outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Compare International Index of Erectile Function Outcomes between control and treatment groups at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile Curvature Compared to Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Compare penile curvature changes (degrees) in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH) - using goniometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile Length Compared to Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Compare penile length changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Peyronie's Disease Questionnaire to Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Compare PDQ changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH) using the Peyronie's Disease Questionnaire (15 items; subdomains - psychological and physical (Q1-6, 0-24), penile pain (Q7-9; 0-30), symptom bother (Q10-15; 0-16); 12 and 14 (Y/N q's); lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare International Index of Erectile Function to baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Compare International Index of Erectile Function changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile Length Between Groups</measure>
    <time_frame>6 months</time_frame>
    <description>Compare penile length changes between control and treatment groups at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events - 6 months - pain, sensation, swelling</measure>
    <time_frame>6 months</time_frame>
    <description>Report adverse events at the 6-month time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events - 12 months - pain, sensation, swelling</measure>
    <time_frame>12 months</time_frame>
    <description>Report adverse events at the 12-month time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in penile curvature durability</measure>
    <time_frame>6 months</time_frame>
    <description>Report changes in penile curvature degree between the 6 and 12-month assessments for CCH men by goniometer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Peyronie's Disease</condition>
  <arm_group>
    <arm_group_label>Control - Crossover to CCH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is &lt;15 degrees). Final assessments would then be performed 6 weeks following the final injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Collagenase Clostridium Histolyticum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is &lt;15 degrees). Men would then undergo assessments 6 weeks later, followed by a 6-month no treatment phase and then final assessments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCH administration</intervention_name>
    <description>Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.</description>
    <arm_group_label>Collagenase Clostridium Histolyticum</arm_group_label>
    <other_name>Collagenase Clostridium Histolyticum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control - Crossover to CCH</intervention_name>
    <description>Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.</description>
    <arm_group_label>Control - Crossover to CCH</arm_group_label>
    <other_name>Collagenase Clostridium Histolyticum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RestoreX</intervention_name>
    <description>Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.</description>
    <arm_group_label>Collagenase Clostridium Histolyticum</arm_group_label>
    <arm_group_label>Control - Crossover to CCH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men with Peyronie's Disease&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Curvature â‰¥30 degrees&#xD;
&#xD;
          -  Previously completed 6-8 CCH injections&#xD;
&#xD;
          -  Prior minimal (&lt;20% and/or &lt;10 degrees) responsiveness to CCH administration&#xD;
&#xD;
          -  Prior CCH injections must have been performed without use of a Restorex traction&#xD;
             device and used the IMPRESS protocol&#xD;
&#xD;
          -  Ability to achieve an erection satisfactory for intercourse with or without PDE5&#xD;
             inhibitors&#xD;
&#xD;
          -  The patient exhibits a palpable plaque consistent with Peyronie's Disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior surgical treatment on the penis (other than circumcision)&#xD;
&#xD;
          -  Any contraindications to CCH - as determined by the PI&#xD;
&#xD;
          -  Inability to complete 8 additional CCH injections&#xD;
&#xD;
          -  Severe plaque calcification (i.e. &gt;1 cm shadowing)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Landon Trost, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CURE PD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Landon Trost, MD</last_name>
    <phone>801-655-0015</phone>
    <email>email@mfp.clinic</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Male Fertility and Peyronie's Clinic</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Landon Trost, MD</last_name>
      <phone>888-655-0015</phone>
      <email>trost.landon@mfp.clinic</email>
    </contact>
    <investigator>
      <last_name>Benjamin D. Green, Economics/MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Holli Burgon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT05108558/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

